Working… Menu

ETEC Logistics Trial (TREK) (Trek)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00516659
Recruitment Status : Completed
First Posted : August 15, 2007
Last Update Posted : March 14, 2012
Information provided by (Responsible Party):
Intercell USA, Inc.

Brief Summary:
This is a multicenter, double-blind, randomized, placebo-controlled field trial to evaluate the epidemiology of natural infection with ETEC occurring after transcutaneous immunization in a field setting.

Condition or disease Intervention/treatment Phase
Diarrhea Biological: Heat-Labile Enterotoxin of Escherichia coli (LT) Biological: Placebo Phase 2

Detailed Description:

The primary objectives of the study are to evaluate the incidence of ETEC illness in a field setting and to compare the safety of LT delivered by TCI with placebo. The secondary objectives include, but are not limited to:

evaluate the stool frequency per episode of ETEC illness in placebo recipients, to evaluate the immunogenicity of LT delivered by TCI, to evaluate the incidence of IBS following travel to areas of ETEC endemnicity, and to evaluate the incidence of VPO in placebo and LT patch recipients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 201 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double (Participant, Investigator)
Official Title: A Phase II, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection With Enterotoxigenic Escherichia Coli Occurring After Transcutaneous Immunization in a Field Setting
Study Start Date : May 2006
Actual Primary Completion Date : January 2007
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diarrhea

Arm Intervention/treatment
Active Comparator: Group 1
Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
Biological: Heat-Labile Enterotoxin of Escherichia coli (LT)
Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.

Placebo Comparator: Group 2
Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)
Biological: Placebo
The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.

Primary Outcome Measures :
  1. Incidence of Enterotoxigenic Escherichia coli (ETEC) illness defined as a diarrheal episode associated with an LT, LT/ST, or ST-positive ETEC strain isolated from a sample of a stool [ Time Frame: during the diarrheal episode or within 48 hours after the last stool in the diarrheal episode. ]
  2. Safety of heat-labile enterotoxin of Escherichia coli (LT) delivered by transcutaneous immunization (TCI) vs placebo [ Time Frame: From vaccination 1 to completion of Day 180 follow-up, about a seven month time period ]

Secondary Outcome Measures :
  1. Stool frequency per episode of ETEC illness in placebo recipients [ Time Frame: Duration of stay in Mexico or Guatemala assessed up to four weeks ]
  2. Immunogenicity of LT delivered by TCI [ Time Frame: at least three weeks prior to arrival in country, arrival in Mexico or Guatemala, and 5 to 18 days after arrival ]
  3. Incidence of irritable bowel syndrome following travel to areas of ETEC endemnicity. [ Time Frame: Baseline through six months post return from Latin America. A period of about six months. ]
  4. Incidence of vaccine preventable outcome in placebo and LT patch recipients. [ Time Frame: Duration of each individual participant stay in Mexico or Guatemala ranging from 7 to 28 Days. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy adult men and women 18-64 years of age inclusive at screening
  • Signed Informed Consent form
  • Planned travel to an area within 2 ½ hours traveling distance of Cuernavaca or Guadalajara, Mexico or Antigua, Guatemala (minimum stay of 7 days)
  • If female who is not post-menopausal or surgically sterile, negative pregnancy test (within 24 hours prior to vaccination) and agreement to employ an effective form of birth control or practice abstinence through the end of the study.

Exclusion Criteria:

  • Clinically significant abnormalities as determined by the Investigator/clinician during physical inspection
  • Received investigational product from 30 days before date of first vaccination or during the entire study period
  • Ever received LT, ETEC, or cholera vaccine
  • History of traveler's diarrhea within the previous year
  • Travel to a developing country within the last year
  • Women who are pregnant or breastfeeding
  • History of achlorhydria
  • Evidence of immunosuppression, including concomitant immunosuppressive therapy; fever > 99.5°F (37.5°C) on day of vaccination
  • Current problems with alcohol or substance abuse
  • An employee of the study clinic
  • Sensitivity or allergy to any of the vaccine components
  • History of significant blood loss, blood product donation, or blood product recipient in the previous 60 days
  • Planned use of Imodium or antibiotics for self treatment of diarrhea during the study period
  • Visible tattoos or marks (tattoos/scars) at the vaccination areas that would prevent appropriate dermatologic monitoring of the vaccination sites; and
  • Medical history of acute or chronic GI illness or major GI surgery.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00516659

Layout table for location information
United States, California
West Coast Clinical Trials
Long Beach, California, United States, 90806
United States, Illinois
Radiant Research
Chicago, Illinois, United States, 60610
United States, Maryland
Johns Hopkins University, Bloomberg School of Public Health
Baltimore, Maryland, United States, 21205
United States, Minnesota
Twin Cities Clinical Research
Minneapolis, Minnesota, United States, 55430
United States, New Jersey
Advanced Biomedical Research
Hackensack, New Jersey, United States, 07601
United States, New York
Asthma Allergy & Associates
Ithica, New York, United States, 14850
United States, Ohio
Radiant Research
Columbus, Ohio, United States, 43212
United States, Texas
Radiant Research
Dallas, Texas, United States, 75235
Breco Research
Houston, Texas, United States, 77024
Center for Infectious Diseases, The University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030
Radiant Research
San Antonio, Texas, United States, 78229
United States, Utah
Jean Brown Research
Salt Lake City, Utah, United States, 84124
United States, Washington
Northwest Kinetics
Tacoma, Washington, United States, 98418
Private Clinic Antigua
Antigua Guatemala, Guatemala, 03001
Private Clinic San Miguel
San Miguel de Allende, Guanajuata, Mexico, 37700
Private Clinic Guadalajara
Guadalajara, Jalisco, Mexico, 44690
AmeriMed Hospital
Puerto Vallarta, Marina Vallarta, Mexico, 48334
Private Clinic Cuernavaca
Cuernavaca, Morelos, Mexico, 62250
Hospital Americano
Cancun, Quintana Roo, Mexico, 77500
Sponsors and Collaborators
Intercell USA, Inc.
Layout table for investigator information
Principal Investigator: Herbert L. DuPont, MD Center for Infectious Diseases, The University of Texas Health Science Center at Houston
Principal Investigator: Robin McKenzie, MD Johns Hopkins University, Bloomberg School of Public Health
Principal Investigator: Rama Yerramsetti Breco Research, Houston, TX
Principal Investigator: William P Jennings Radiant Research, San Antonio, TX
Principal Investigator: Yu-Luen Hsu West Coast Clinical Trials, Long Beach, CA
Principal Investigator: Christopher A Smith Asthma & Allergy Associates, Ithaca, NY
Principal Investigator: Benno G Roesch Advanced Biomedical Research, Hackensack, NJ
Principal Investigator: Jeffrey G Geohas Radiant Research, Chicago, IL
Principal Investigator: Gilbert Podolsky Jean Brown Research, Salt Lake City, UT
Principal Investigator: Thomas Lagen Northwest Kinetics, Tacoma, WA
Principal Investigator: Roy M Fleischmann Radiant Research, Dallas, TX
Principal Investigator: Douglas R Schumacher Radiant Research, Columbus, OH
Principal Investigator: Norman M Lunde Twin Cities Clinical Research, Minneapolis, MN
Principal Investigator: Francisco G Sandoval Universidad Autonoma De Guadalajara, Mexico
Principal Investigator: Juan Hector M Romero Universidad Autonoma Guadalajara, Mexico
Principal Investigator: Jaime B Gerson University of Texas, Cuernavaca, Mexico
Principal Investigator: Edwin Asturias Universidad del Valle de Guatemala (Antigua)
Principal Investigator: Roberto Garcia AmeriMed Puerto Vallarta, Mexico
Principal Investigator: Martha V Serrato Hospital Americano, Cancun, Mexico
Principal Investigator: Robert Maxwell Private Clinic, San Miguel de Allende, Mexico

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Intercell USA, Inc. Identifier: NCT00516659     History of Changes
Other Study ID Numbers: ELT206
First Posted: August 15, 2007    Key Record Dates
Last Update Posted: March 14, 2012
Last Verified: March 2012
Keywords provided by Intercell USA, Inc.:
Traveler's diarrhea
patch vaccine
diarrhea prevention
epidemiology ETEC
Escherichia coli
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive
Signs and Symptoms
Immunologic Factors
Physiological Effects of Drugs